Loading stock data…
IRMD
$87.15+3.71 (+4.45%)
Market ClosedLast close May 1
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IRADIMED CORPORATION in the Healthcare sector is trading at $87.15. The stock is currently 19% below its 52-week high of $107.90, remaining 1.7% above its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why IRMD maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$87.15
Potential Downside
55.9%
Whystock Fair Value$38.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$118.67+36.2%
Range$116.00 – $120.00
Fundamentals
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
50.74
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Strong income play. Yield provides a meaningful total return floor.
90.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.83%
Volume
Today's trading volume
346,571
Recent News
iRadimed Corp (IRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and New Product Demand
iRadimed Corp (IRMD) reports a 13% revenue increase and robust demand for its new MR IV pump system, despite production challenges.
Why Iradimed Stock Topped the Market Today
Yet again, it posted growth and robust profitability in its latest quarter.
iRadimed Q1 Earnings Call Highlights
iRadimed (NASDAQ:IRMD) reported second-quarter 2025 results that management said marked the company’s 16th consecutive quarter of record revenues, driven by strength in its MRI-compatible infusion pump business and continued growth in patient monitoring. For the quarter ended June 30, 2025, revenue
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
iRadimed (IRMD) delivered earnings and revenue surprises of +8.89% and +1.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Evolving Story For IRADIMED (IRMD) Is Shaping Analyst Targets And Fair Value
IRADIMED’s updated analyst narrative keeps the fair value anchor steady at $118.67, so the headline price target reference point in the model is unchanged. That level is now being echoed by bullish analysts setting targets around the same mark, reflecting their confidence in the assumptions currently driving coverage. In the sections that follow, you will see how this evolving narrative is taking shape and how to track it over time. Analyst Price Targets don't always capture the full story...